- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05472259
A Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC (NALPAC) (NALPAC)
A Non-comparative Randomized Phase 2 Study, Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for Metastatic Pancreatic Ductal Adenocarcinoma (PDAC), Progressive After Gemcitabine-Abraxane or Gemcitabine Monotherapy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Based on the results of previous studies, the sponsor aims to assess efficacy and safety of this triplet (irinotecan, 5FU/LV and oxaliplatin) in second-line treatment in fit patients (ECOG 0-1) metastatic PDAC.
The primary objective is to assess the efficacy of NALIRINOX (= investigational arm) and NALIRI (= standard care arm) in terms of Progression-Free Survival Rate (PFSR).
As secondary objectives, the following will be evaluated in both arms:
- Safety/toxicity and tolerability profile according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 5.
- Progression free survival (PFS)
- Overall response rate and duration of response as assessed by imaging (RECIST 1.1) and tumor markers
- Overall survival (OS)
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Lina Dewever
- Phone Number: +32 (0) 479 36 63 82
- Email: lina.dewever@bgdo.org
Study Contact Backup
- Name: Ine De Bruyne
- Phone Number: +32 (0) 478 81 04 27
- Email: i.debruyne@bgdo.org
Study Locations
-
-
-
Antwerp, Belgium, 2650
- Not yet recruiting
- UZ Antwerpen
-
Contact:
- Sanne Wouters
-
Principal Investigator:
- Timon Vandamme, Prof
-
Bonheiden, Belgium
- Recruiting
- AZ Imelda
-
Contact:
- Doreen Iwens
-
Principal Investigator:
- Pieter-Jan Cuyle, Dr.
-
Brussels, Belgium, 1070
- Not yet recruiting
- ULB Erasme
-
Contact:
- Axelle Ghilain
-
Principal Investigator:
- Jean-Luc Van Laethem, Dr
-
Brussels, Belgium, 1200
- Not yet recruiting
- Cliniques Universitaires Saint-Luc UCL
-
Contact:
- Tuan Le
-
Principal Investigator:
- Ivan Borbath, Prof
-
Charleroi, Belgium
- Not yet recruiting
- Grand Hopital de Charleroi
-
Contact:
- Matthias Papier
-
Principal Investigator:
- Javier Carrasco, Dr.
-
Ghent, Belgium
- Not yet recruiting
- AZ Maria Middelares
-
Contact:
- Margaux Vansteelant
-
Principal Investigator:
- Els Monsaert, Dr.
-
Ghent, Belgium
- Not yet recruiting
- University Hospital Ghent
-
Contact:
- Tine Derre
-
Principal Investigator:
- Karen Geboes, Prof.
-
Liège, Belgium, 4000
- Not yet recruiting
- CHC MontLegia
-
Contact:
- Jocelyne Gilson
-
Principal Investigator:
- Ghislain Houbiers, Dr
-
Mechelen, Belgium
- Not yet recruiting
- Az Sint-Maarten
-
Contact:
- Katrien Beullens
-
Principal Investigator:
- Leen Mortier, Dr.
-
Mons, Belgium
- Not yet recruiting
- CHU Ambroise Pare
-
Contact:
- Mariane Blockmans
-
Principal Investigator:
- Marie Diaz, Dr.
-
Namur, Belgium
- Not yet recruiting
- CHR Namur
-
Contact:
- Christine Leon
-
Principal Investigator:
- Yeter Gokburun, Dr.
-
-
West-Vlaanderen
-
Brugge, West-Vlaanderen, Belgium
- Not yet recruiting
- AZ St-Lucas
-
Contact:
- Tania Maerten
-
Principal Investigator:
- Liesbeth Holvoet, Dr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically proven metastatic adenocarcinoma of the pancreas
- Progression documented after gemcitabine-Abraxane, or gemcitabine monotherapy
- Signed written informed consent
- Age ≥ 18
- ECOG PS 0/1 at study entry
- Measurable disease
- Adequate renal (serum creatinine ≤ 1.5x upper reference range), liver (total bilirubin ≤ 1.5x upper reference range) and hematopoietic functions (PMN ≥ 1,5x109/L, platelets ≥ 100x109/L, hemoglobin ≥ 9g/dl)
- INR/PTT ≤ 1.5x ULN
- Life expectancy of at least 12 weeks
- Effective contraception for both male and female patients if the risk of conception exists during treatment and for one month after the last administration
- Peripheral Neuropathy < grade 2
Exclusion Criteria:
- Uncontrolled concurrent CNS, cardiac, infectious diseases, hypertension
- History of myocardial infarction, deep venous or arterial thrombosis, CVA during the last 6 months
- Known hypersensitivity to any of the components, including excipients, of study treatments
- Previous malignancy in the last past 3 years except basal cell cancer of the skin or preinvasive cancer of the cervix or carcinoma in situ of any type
- Pregnancy or breast feeding
- Medical or psychological conditions that would not permit the patient to complete the study or sign inform consent
- Unstable angina, congestive heart failure ≥NYHA class II
- Uncontrolled hypertension despite optimal management (systolic blood pressure >150 mmHg or diastolic pressure > 90mmHg)
- HIV infection
- Complete DPD deficiency
- Liver failure, cirrhosis Child Pugh B or C
- Active chronic hepatitis B or C with a need for antiviral treatment
- Brain metastasis
- Major surgery, open biopsy or significant traumatic injury within 4 weeks prior to the first dose of treatment
- History of organ allograft
- Ongoing uncontrolled, serious infection
- Renal failure requiring dialysis
- Patients receiving or having received any investigational treatment within 4 weeks prior to study entry, or participating to another clinical study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Arm A NALIRI
Cycle length: 14 days Day 1:
|
In the control arm (Naliri) a dose of 70mg/m² is administered in combination with 5FU and leucovorin In the investigational arm (Nalirinox) a dose of 50mg/m² is administered in combination with 5FU, leucovorin and oxaliplatin
Other Names:
In the control arm (Naliri) a dose of 2400 mg/m² is administered in combination with nanoliposomal irinotecan and leucovorin In the investigational arm (Nalirinox) a dose of 2400 mg/m² is administered in combination with nanoliposomal irinotecan, leucovorin and oxaliplatin
Other Names:
In the control arm (Naliri) a dose of 400 mg/m² is administered in combination with nanoliposomal irinotecan and 5FU In the investigational arm (Nalirinox) a dose of 400 mg/m² is administered in combination with nanoliposomal irinotecan, 5FU and oxaliplatin
Other Names:
|
Experimental: Arm B NALIRINOX
Cycle length: 14 days Day 1:
|
In the control arm (Naliri) a dose of 70mg/m² is administered in combination with 5FU and leucovorin In the investigational arm (Nalirinox) a dose of 50mg/m² is administered in combination with 5FU, leucovorin and oxaliplatin
Other Names:
In the control arm (Naliri) a dose of 2400 mg/m² is administered in combination with nanoliposomal irinotecan and leucovorin In the investigational arm (Nalirinox) a dose of 2400 mg/m² is administered in combination with nanoliposomal irinotecan, leucovorin and oxaliplatin
Other Names:
In the control arm (Naliri) a dose of 400 mg/m² is administered in combination with nanoliposomal irinotecan and 5FU In the investigational arm (Nalirinox) a dose of 400 mg/m² is administered in combination with nanoliposomal irinotecan, 5FU and oxaliplatin
Other Names:
Only administered in the investigational arm (Nalirinox): a dose of 60 mg/m² is administered in combination with nanoliposomal irinotecan, 5FU and Leucovorin
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy of NALIRINOX and NALIRI through Progression-Free Survival at D85
Time Frame: at day 85 from randomization
|
NALIRINOX is the investigational arm and NALIRI is the standard care arm.
The efficacy will be assessed in terms of the Progression-Free Survival Rate (PFSR).
This is defined as the proportion of patients alive and free of progression at day 85.
|
at day 85 from randomization
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety/toxicity and tolerability profil: Severety of adverse events
Time Frame: until 14 days after End of Treatment
|
Adverse events and Serious Adverse events will be assessed during the study treatment and until 14 days later.
Severety will be graded according to the NCI-CTCAE version 5.0 and relationship to the study medication will be defined.
|
until 14 days after End of Treatment
|
Safety/toxicity and tolerability profil: Laboratory assessments
Time Frame: until 14 days after End of Treatment
|
Standard laboratory safety assessments: They are mandatory prior to each administration of study medication and at the 15 days follow-up visit. Clinically significant vs not clinically significant. |
until 14 days after End of Treatment
|
Safety/toxicity and tolerability profil: ECOG
Time Frame: until 14 days after End of Treatment
|
WHO ECOG performance status (PS) will be defined prior to each administration of study medication and at the 15 days follow-up visit following the ECOG Performance Status Scale.
|
until 14 days after End of Treatment
|
Safety/toxicity and tolerability profil: review of body systems
Time Frame: until 14 days after End of Treatment
|
A full review of body systems will be performed: heart rate, blood pressure, respiratory rate, body temperature, height, weight and ECG (screening visit only, unless clinically indicated). Clinically significant versus not clinically significant |
until 14 days after End of Treatment
|
Progression Free Survival and sensitivity analysis: Effect of Center on prognostic factors
Time Frame: From date of first study treatment administration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years after End of Treatment.
|
The effect of potential prognostic factors will be assessed through sensitivity analyses, including:
|
From date of first study treatment administration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years after End of Treatment.
|
Progression Free Survival and sensitivity analysis: Effect of tumor location on prognostic factors
Time Frame: From date of first study treatment administration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years after End of Treatment
|
The effect of potential prognostic factors will be assessed through sensitivity analyses, including:
|
From date of first study treatment administration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years after End of Treatment
|
Progression Free Survival and sensitivity analysis: Effect of previous chemotherapy on prognostic factors
Time Frame: From date of first study treatment administration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years after End of Treatment
|
The effect of potential prognostic factors will be assessed through sensitivity analyses, including:
|
From date of first study treatment administration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years after End of Treatment
|
Progression Free Survival and sensitivity analysis: effect of ECOG on prognostic factors
Time Frame: From date of first study treatment administration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years after End of Treatment
|
The effect of potential prognostic factors will be assessed through sensitivity analyses, including:
|
From date of first study treatment administration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years after End of Treatment
|
Objective tumor response: Rate of complete response and partial response
Time Frame: performed within 28 days before start therapy, 3 times every 6 weeks and afterwards every 8 weeks
|
Tumor (response) evaluation will be performed according to RECIST criteria v. 1.1 (CT scan thorax, abdomen and pelvis or MRI abdomen and pelvis + CT chest) based upon the investigator's assessment.
Overall response is defined as a best response of either CR or PR (CR+PR).
|
performed within 28 days before start therapy, 3 times every 6 weeks and afterwards every 8 weeks
|
Duration of overall survival
Time Frame: Time from Day 1 of therapy to death until maximum 5 years after End of Treatment
|
For patients who are still alive at the time of study analysis or who are lost to follow up, survival will be censored at the last recorded date that the patient is known to be alive or at the date of data cut-off, whatever occurs earlier.
|
Time from Day 1 of therapy to death until maximum 5 years after End of Treatment
|
Duration of disease control
Time Frame: From date of first study treatment administration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years after End of Treatment
|
Disease control is defined as a best response of either CR, PR, or SD (CR+PR+SD).
|
From date of first study treatment administration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years after End of Treatment
|
Duration of response
Time Frame: Time from measurement criteria are first met for CR/PR to either the first time disease progression is documented or death (for not progressed patients who deceased within 60 days from last tumor assessment) until maximum 5 years after EOT
|
The duration of response will be censored on the date of last known tumor assessment for not progressed patients lost to follow up or deceased prior to the next planned tumor assessment (within 60 days).
Not evaluable patients at one time point assessment will be censored at the date of last known assessment.
|
Time from measurement criteria are first met for CR/PR to either the first time disease progression is documented or death (for not progressed patients who deceased within 60 days from last tumor assessment) until maximum 5 years after EOT
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Exploratory lab investigation for potential prognostic and predictive biomarkers on blood and tumor samples
Time Frame: Sapmples will be collected throughout the study and shipped to the sponsor maximum 1 year after last 15 day follow-up visit
|
Translational research will be performed for potential prognostic and predictive biomarkers. For that purpose, plasma samples will be kept in the selected centres' biobanks. The translational research will be carried out on tumor samples collected before the start of treatment and on blood samples collected as per below. Tumor tissue: 10 slices of the paraffin embedded tissue collected during the diagnosis of the disease will be collected. Blood samples: Two 10 ml blood samples from each patient who consents to participate in the biological study will be collected before the start of the treatment, and before each cycle till the discontinuation of the treatment. The exact measurements that will be done, have not been defined yet. |
Sapmples will be collected throughout the study and shipped to the sponsor maximum 1 year after last 15 day follow-up visit
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Ivan Borbath, University hospital St-luc, Brussel
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Adenocarcinoma
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Protective Agents
- Topoisomerase Inhibitors
- Micronutrients
- Vitamins
- Topoisomerase I Inhibitors
- Antidotes
- Vitamin B Complex
- Fluorouracil
- Oxaliplatin
- Leucovorin
- Irinotecan
Other Study ID Numbers
- NALPAC
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Pancreatic Ductal Adenocarcinoma
-
Georgetown UniversityERYtech PharmaActive, not recruitingMetastatic Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal AdenocarcinomaUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingPancreatic Cancer | Pancreatic Cancer Metastatic | Pancreatic Cancer Stage IV | Metastatic Pancreatic Carcinoma | Metastatic Pancreatic Adenocarcinoma | Pancreatic Carcinoma | Metastatic Pancreatic Cancer | Pancreatic Cancer Non-resectable | Metastatic Pancreatic Ductal Adenocarcinoma | Pancreatic Carcinoma... and other conditionsUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingPancreatic Cancer | Pancreatic Ductal Adenocarcinoma | Metastatic Pancreatic Cancer | Metastatic Pancreatic Ductal Adenocarcinoma | Primary Pancreatic Ductal AdenocarcinomaUnited States
-
Roswell Park Cancer InstituteNot yet recruitingStage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma | Advanced Pancreatic Ductal Adenocarcinoma | Unresectable Pancreatic Ductal Adenocarcinoma and other conditionsUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingPancreatic Cancer | Pancreatic Cancer Metastatic | Pancreatic Ductal Adenocarcinoma | Pancreatic Carcinoma | Metastatic Pancreatic Cancer | Metastatic Pancreatic Ductal AdenocarcinomaUnited States
-
Sierra Oncology LLC - a GSK companyTerminatedMetastatic Pancreatic Ductal AdenocarcinomaUnited States
-
PfizerCelgeneCompletedMetastatic Pancreatic Ductal AdenocarcinomaUnited States, Spain
-
British Columbia Cancer AgencyCanadian Cancer Society (CCS); SignalChem Lifesciences CorporationRecruitingMetastatic Pancreatic Ductal AdenocarcinomaCanada
-
University Hospital, AntwerpUniversitair Ziekenhuis Brussel; General Hospital Groeninge; AZ Nikolaas; Erasme... and other collaboratorsActive, not recruitingMetastatic Pancreatic Ductal AdenocarcinomaBelgium
-
PfizerTerminatedMetastatic Pancreatic Ductal AdenocarcinomaUnited States
Clinical Trials on Nanoliposomal irinotecan
-
Stony Brook UniversityUniversity of Iowa; Ipsen; Barbara Ann Karmanos Cancer InstituteCompletedGastric Cancer | Colorectal Cancer | Mesothelioma | Pseudomyxoma Peritonei | Peritoneal Cancer | Mucinous Adenocarcinoma | Primary Peritoneal Carcinoma | Mucinous TumorUnited States
-
National Health Research Institutes, TaiwanChina Medical University Hospital; Taipei Veterans General Hospital, Taiwan; National... and other collaboratorsCompleted
-
PharmaEngineCompletedRefractory Solid TumorsTaiwan
-
University of California, San FranciscoNational Cancer Institute (NCI); IpsenCompletedHigh Grade GliomaUnited States
-
University Hospital, AntwerpUniversitair Ziekenhuis Brussel; General Hospital Groeninge; AZ Nikolaas; Erasme... and other collaboratorsActive, not recruitingMetastatic Pancreatic Ductal AdenocarcinomaBelgium
-
Sabine Mueller, MD, PhDPacific Pediatric Neuro-Oncology Consortium; The V Foundation for Cancer ResearchCompletedDiffuse Intrinsic Pontine GliomaUnited States
-
University of California, San FranciscoCompletedGlioblastoma | Gliosarcoma | Anaplastic Astrocytoma | Anaplastic OligodendrogliomaUnited States
-
National Health Research Institutes, TaiwanChina Medical University Hospital; Chang Gung Memorial Hospital; Kaohsiung Medical... and other collaboratorsNot yet recruiting
-
Brown UniversityRhode Island Hospital; Merrimack PharmaceuticalsTerminatedGlioblastoma | Glioblastoma Multiforme | GBMUnited States
-
Emory UniversityIpsen; Taiho Oncology, Inc.RecruitingGastric Adenocarcinoma | Unresectable Pancreatic Carcinoma | Metastatic Pancreatic Adenocarcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Colorectal Adenocarcinoma | Stage IV Gastric Cancer | Stage IV Colorectal Cancer | Stage IVA Colorectal Cancer | Stage IVB Colorectal Cancer | Stage... and other conditionsUnited States